{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:48:49Z","timestamp":1784288929684,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.intimp.2021.108216","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T10:27:07Z","timestamp":1633775227000},"page":"108216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"PB","title":["Immune response of C57BL\/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants"],"prefix":"10.1016","volume":"101","author":[{"given":"Lei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2021.108216_b0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00013542-199310000-00006","article-title":"Epidemiology, outcome and control of varicella-zoster infection.","volume":"4","author":"Miller","year":"1993","journal-title":"Revi. Med. Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108216_b0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1128\/CMR.00052-13","article-title":"Pathogenesis and current approaches to control of varicella-zoster virus infections","volume":"26","author":"Gershon","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"issue":"RR-5","key":"10.1016\/j.intimp.2021.108216_b0015","first-page":"1","article-title":"Committee on Immunization Practices Centers for Disease, Prevention, Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2021.108216_b0020","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.013","article-title":"Risk of Stroke\/Transient Ischemic Attack or Myocardial Infarction with Herpes Zoster: A Systematic Review and Meta-Analysis","volume":"26","author":"Zhang","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2021.108216_b0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2009.09.010","article-title":"Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity","volume":"351","author":"Otani","year":"2009","journal-title":"J. Immunol. Methods"},{"issue":"6","key":"10.1016\/j.intimp.2021.108216_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.intimp.2021.108216_b0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4161\/hv.34363","article-title":"Reducing the burden of Herpes Zoster in Italy","volume":"11","author":"Gabutti","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"11","key":"10.1016\/j.intimp.2021.108216_b0040","doi-asserted-by":"crossref","first-page":"e3789","DOI":"10.1371\/journal.pone.0003789","article-title":"Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka","volume":"3","author":"Malavige","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2021.108216_b0045","doi-asserted-by":"crossref","unstructured":"A. Weinberg, J.H. Zhang, M.N. Oxman, G.R. Johnson, A.R. Hayward, M.J. Caulfield, M.R. Irwin, J. Clair, J.G. Smith, H. Stanley, R.D. Marchese, R. Harbecke, H.M. Williams, I.S. Chan, R.D. Arbeit, A.A. Gershon, F. Schodel, V.A. Morrison, C.A. Kauffman, S.E. Straus, K.E. Schmader, L.E. Davis, M.J. Levin, US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators, Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine, J. Infect. Dis. 200(7) (2009) 1068\u20131077.","DOI":"10.1086\/605611"},{"issue":"1","key":"10.1016\/j.intimp.2021.108216_b0050","first-page":"1","article-title":"Herpes zoster vaccination in the elderly subjects: improving awareness and uptake","volume":"7","author":"Gabutti","year":"2015","journal-title":"Patient Intell."},{"issue":"22","key":"10.1016\/j.intimp.2021.108216_b0055","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"Prevention Study, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.108216_b0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr. Opin. Immunol."},{"issue":"22","key":"10.1016\/j.intimp.2021.108216_b0065","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.108216_b0070","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2021.108216_b0075","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2021.108216_b0080","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.108216_b0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59((R)) adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O'Hagan","year":"2013","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10.1016\/j.intimp.2021.108216_b0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.108216_b0095","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/196952a0","article-title":"Action of saponin on biological cell membranes","volume":"196","author":"Bangham","year":"1962","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.intimp.2021.108216_b0100","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.vaccine.2019.05.059","article-title":"Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ)","volume":"37","author":"Cawlfield","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2021.108216_b0105","doi-asserted-by":"crossref","first-page":"e59081","DOI":"10.1371\/journal.pone.0059081","article-title":"M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A","volume":"8","author":"Ibanez","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.intimp.2021.108216_b0110","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2014.10.078","article-title":"Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination","volume":"33","author":"Leroux-Roels","year":"2015","journal-title":"Vaccine"},{"issue":"6522","key":"10.1016\/j.intimp.2021.108216_b0115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.intimp.2021.108216_b0120","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.intimp.2021.108216_b0125","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1016\/j.vaccine.2008.05.083","article-title":"Neonatal immune response and serum bactericidal activity induced by a meningococcal conjugate vaccine is enhanced by LT-K63 and CpG2006","volume":"26","author":"Brynjolfsson","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.intimp.2021.108216_b0130","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1080\/21645515.2019.1596710","article-title":"RSV recombinant candidate vaccine G1F\/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs","volume":"15","author":"Li","year":"2019","journal-title":"Human Vaccines Immunotherapeut."},{"issue":"1","key":"10.1016\/j.intimp.2021.108216_b0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2021.108216_b0140","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/intimm\/dxw017","article-title":"CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE)","volume":"28","author":"Makinen","year":"2016","journal-title":"Int. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2021.108216_b0145","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02257-16","article-title":"Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir","volume":"91","author":"Hensel","year":"2017","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/j.intimp.2021.108216_b0150","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1016\/j.vaccine.2020.03.020","article-title":"Recombinant E(rns)-E2 protein vaccine formulated with MF59 and CPG-ODN promotes T cell immunity against bovine viral diarrhea virus infection","volume":"38","author":"Wang","year":"2020","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.intimp.2021.108216_b0155","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1016\/j.vaccine.2018.07.006","article-title":"Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants","volume":"36","author":"Shi","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2021.108216_b0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00430-019-00579-9","article-title":"Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant","volume":"208","author":"Chen","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.intimp.2021.108216_b0165","doi-asserted-by":"crossref","first-page":"526965","DOI":"10.3389\/fimmu.2020.526965","article-title":"Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB\/c Mice","volume":"11","author":"Zheng","year":"2020","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2021.108216_b0170","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2019.02.048","article-title":"Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice","volume":"37","author":"Wui","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2021.108216_b0175","article-title":"Mouse Body Temperature Measurement Using Infrared Thermometer During Passive Systemic Anaphylaxis and Food Allergy Evaluation","volume":"139","author":"Kawakami","year":"2018","journal-title":"J. Visualized Exp. : JoVE"},{"issue":"4","key":"10.1016\/j.intimp.2021.108216_b0180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/infdis\/jiu500","article-title":"Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection","volume":"211","author":"Schub","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2021.108216_b0185","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1073\/pnas.1519690113","article-title":"Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood","volume":"113","author":"Nakaya","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"12","key":"10.1016\/j.intimp.2021.108216_b0190","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","article-title":"Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia","volume":"217","author":"Baraniak","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.108216_b0195","doi-asserted-by":"crossref","first-page":"e52687","DOI":"10.7554\/eLife.52687","article-title":"Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway","volume":"9","author":"Kim","year":"2020","journal-title":"eLife"},{"issue":"8","key":"10.1016\/j.intimp.2021.108216_b0200","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4049\/jimmunol.148.8.2357","article-title":"Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses","volume":"148","author":"Newman","year":"1992","journal-title":"J. Immunol."},{"issue":"7258","key":"10.1016\/j.intimp.2021.108216_b0205","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.321.7258.424","article-title":"Th1 and Th2 responses: what are they?","volume":"321","author":"Berger","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2021.108216_b0210","first-page":"663","article-title":"Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21","volume":"7","author":"Welsby","year":"2016","journal-title":"Front. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2021.108216_b0215","first-page":"1","article-title":"Saponins as vaccine adjuvants","volume":"13","author":"Kensil","year":"1996","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"20","key":"10.1016\/j.intimp.2021.108216_b0220","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2021.108216_b0225","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1515\/bmc-2018-0007","article-title":"Interferon-gamma (IFN-gamma): Exploring its implications in infectious diseases","volume":"9","author":"Kak","year":"2018","journal-title":"Biomolecular Concepts"},{"issue":"21","key":"10.1016\/j.intimp.2021.108216_b0230","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01151-18","article-title":"Distinctive Roles for Type I and Type II Interferons and Interferon Regulatory Factors in the Host Cell Defense against Varicella-Zoster Virus","volume":"92","author":"Sen","year":"2018","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108216_b0235","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jim.2015.07.011","article-title":"Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-\u03b3 enzyme-linked immunosorbent assay","volume":"426","author":"Hayashida","year":"2015","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.intimp.2021.108216_b0240","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jmv.25391","article-title":"Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-gamma Enzyme-Linked Immunosorbent Assay in adults >\/=50 years of age administered a herpes zoster vaccine","volume":"91","author":"Yang","year":"2019","journal-title":"J. Med. Virol."}],"updated-by":[{"DOI":"10.1016\/j.intimp.2023.110260","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921008523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921008523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T16:18:08Z","timestamp":1701620288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921008523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"alternative-id":["S1567576921008523"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108216","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.intimp.2023.110260","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune response of C57BL\/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108216"}}